

Disorder	Causative Gene or Region (OMIM#)
Imprinting and Trinucleotide Repeat Disorders	
Angelman syndrome (AS)	15q11.2-q13 (<i>SNRPN</i> promoter, <i>SNURF</i>) (105830)
Beckwith-Wiedemann syndrome (BWS)	11p15 (IC1 and IC2) (130650)
Diabetes mellitus, transient neonatal 1 (TNDM1)	6q24 (<i>PLAG1</i>) (601410)
Fragile X syndrome (FXS)	<i>FMR1</i> promoter (300624)
Kagami-Ogata syndrome (KOS)	14q32 (<i>MEG3</i> promoter) (608149)
Mulchandani-Bhoj-Conlin syndrome (MBCS)	20q11-q13 (<i>GNAS</i>) (617352)
Multi-locus imprinting disturbances (MLID)	All EpiSign™ imprinting regions.
Prader-Willi syndrome (PWS)	15q11.2 (<i>SNRPN</i> promoter, <i>SNURF</i>) (176270)
Pseudohypoparathyroidism, Type Ia, Ib (PHP1A, PHP1B)	20q13.32 (<i>GNAS</i>) (139320, 603233)
Silver-Russel syndrome 1 (SRS1)	11p15 (IC1 and IC2) (180860)
Silver-Russel syndrome 2 (SRS2)	7p13-q32 (618905)
Temple syndrome	14q32 (<i>MEG3</i> promoter) (616222)
Episignature Disorders	
Alpha-thalassemia/Impaired intellectual development syndrome, X-linked (<i>ATRX</i>) and Intellectual disability-hypotonic facies syndrome, X-linked, 1 (<i>MRXHF1</i>) ^{1*}	<i>ATRX</i> (301040, 309580)
Ankylosing spondylitis ^{46*}	<i>IL12B</i> (161561)
Arboleda-Tham syndrome (<i>ARTHS</i>) ²	<i>KAT6A</i> (616268)
ARID1A duplication-related syndrome ^{2,3*}	<i>ARID1A</i> (603024)
Au-Kline syndrome (<i>AUKS</i>) ^{46*}	<i>HNRNPK</i> (616580)
BAFopathies: Coffin-Siris (CSS1-5, 7) & Nicolaides-Baraitser (NCBRS) syndromes ^{4*}	<i>ARID1B</i> , <i>ARID1A</i> , <i>SMARCB1</i> , <i>SMARCA4</i> , <i>SMARCE1</i> , <i>DPF2</i> , <i>SMARCA2</i> (135900, 614607, 614608, 614609, 616938, 618027, 601358)
BAFopathies: Coffin-Siris syndrome 1 & 2 (CSS1, CSS2) ⁵	<i>ARID1B</i> , <i>ARID1A</i> (135900, 614607)
Beck-Fahrner syndrome (<i>BEFAHRS</i>) ^{6,7}	<i>TET3</i> (618798)
Beck-Fahrner syndrome (<i>BEFAHRS</i> _biallelic)	<i>TET3</i> (618798)
Blepharophimosis-impaired intellectual development syndrome (BIS)	<i>SMARCA2</i> (619293)
Börjeson-Forssman-Lehmann syndrome (<i>BFLS</i>) ^{1,2,8}	<i>PHF6</i> (301900)
Branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome (BCAHH) ^{2,9}	<i>KMT2D</i> (620186)
Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant (<i>ADCADN</i>) ²	<i>DNMT1</i> (604121)
CHARGE syndrome	<i>CHD7</i> (214800)
CHD6-related syndrome*	<i>CHD6</i> (616114)
CHD6-related syndrome (<i>CHD6_p986_987</i>) ^{55*}	<i>CHD6</i> (616114)
Chr1p36 deletion syndrome ^{2,10}	Chr1p36 deletion (607872)
Chromosome 19p13.13 deletion syndrome ¹¹	Chr19p13.13del (613638)
Chromosome Xp11.22 duplication syndrome ^{1,2,12}	ChrXp11.22 duplication (300705)
Chromosome 8p inverted duplication/deletion syndrome ⁴⁷	Chr8p invdupdel



Chung-Jansen syndrome (CHUJANS), White-Kernohan syndrome (WHIKERS) and Börjeson-Forssman-Lehmann syndrome (BFLS)	<i>PHIP, DDB1, PHF6</i> (617991, 619426, 301900)
Chung-Jansen syndrome (CHUJANS) ^{2,8} Error! Bookmark not defined.	<i>PHIP</i> (617991)
Clark-Baraitser syndrome (CLABARS)	<i>TRIP12</i> (617752)
Coffin-Siris syndrome 1 (CSS1) ^{2,13}	<i>ARID1B</i> (135900)
Coffin-Siris syndrome 2 (CSS2) ^{2,13}	<i>ARID1A</i> (614607)
Coffin-Siris syndrome 3 (CSS3) ^{2,13}	<i>SMARCB1</i> (614608)
Coffin-Siris syndrome 4 (CSS4) ^{2,13}	<i>SMARCA4</i> (614609)
Coffin-Siris syndrome 4 (CSS4) ^{2,13,14}	<i>SMARCA4</i> c.2656 (614609)
Coffin-Siris syndrome 5 (CSS5) ^{13*}	<i>SMARCE1</i> (616938)
Coffin-Siris syndrome 6 (CSS6)	<i>ARID2</i> (617808)
Coffin-Siris syndrome 7 (CSS7)*	<i>DPF2</i> (618027)
Coffin-Siris syndrome 12 (CSS12) ^{2†}	<i>BICRA</i> (619325)
Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD) ²	<i>CDK13, CCNK</i> (617360)
Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CDK13_truncating) ⁴⁵	<i>CDK13</i> (617360)
Cornelia de Lange syndromes 1-4 (CDLS1, CDLS2, CDLS3, CDLS4) ¹⁵	<i>NIPBL, SMC1A, SMC3, RAD21</i> (122470, 300590, 610759, 614701)
Cornelia de Lange syndrome 1 (CDLS1) ⁵³	<i>NIPBL</i> (122470)
Cornelia de Lange syndrome 2 (CDLS2) ⁵³	<i>SMC1A</i> (300590)
Cornelia de Lange syndrome 3 (CDLS3) ^{51,53}	<i>SMC3</i> (610759)
Cornelia de Lange syndrome 4 (CDLS4) ⁵³	<i>RAD21</i> (614701)
DEGCAGS syndrome ¹⁶	<i>ZNF699</i> (619488)
Desanto-Shinawi syndrome (DESSH) [†]	<i>WAC</i> (616708)
Developmental and epileptic encephalopathy 54 (DEE54)	<i>HNRNPU</i> (617391)
Developmental and epileptic encephalopathy 94 (DEE94)	<i>CHD2</i> (615369)
Developmental delay, dysmorphic facies, and brain anomalies (DEVDFB)*	<i>U2AF2</i> (620535)
Developmental delay with or without dysmorphic facies and autism (DEDDFA) ^{17†}	<i>TRRAP</i> (618454)
Developmental delay with variable intellectual disability and dysmorphic facies (DIDDF)	<i>JARID2</i> (601594)
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy (DIGFAN)*	<i>MORC2</i> (619090)
Developmental delay, hypotonia, musculoskeletal defects, and behavioral abnormalities (DEHMBA) ^{50*}	<i>SRCAP</i> (619595)
Diamond-Blackfan anemia types 1, 4, 5-7, and 10 (DBA1, DBA4, DBA5-7, DBA10) ^{49*}	<i>RPS19, RPS17, RPL35A, RPL5, RPL11, RPS26</i> (105650, 612527, 612528, 612561, 612562, 613309)
Diamond-Blackfan anemia 1 (DBA1) ^{18†}	<i>RPS19</i> (105650)
Diamond-Blackfan anemia 5 (DBA5) ^{18†}	<i>RPL35A</i> (612528)
Diamond-Blackfan anemia types 6 & 7 (DBA6, DBA7)*	<i>RPL5, RPL11</i> (612528, 612561)
Diamond-Blackfan anemia 10 (DBA10)*	<i>RPS26</i> (613309)
Diets-Jongmans syndrome (DIJOS)	<i>KDM3B</i> (618846)
DMAP1-associated syndrome*	<i>DMAP1</i> (605077)

Down syndrome	Chr21 trisomy (190685)
Dystonia 28, Childhood-onset (DYT28)	<i>KMT2B</i> (617284)
Euchromatic Histone-Lysine N-methyltransferase 2 disorder*	<i>EHMT2</i> (604599)
EHMT1 duplication-related syndrome*	<i>EHMT1</i> (607001)
Facioscapulohumeral muscular dystrophy 2, digenic (FSHD2)*	<i>SMCHD1</i> (158901)
Fanconi anemia (FANCA, FANCC, FANCD2, FANCG, FANCI, FANCL) ^{16,19*}	<i>FANCA, FANCC, FANCD2, FANCG, FANCI, FANCL</i> (227650, 613899, 613984, 602956, 611360, 608111)
Fetal valproate syndrome (FVS) ^{20*}	Not applicable (609442)
Floating-Harbor syndrome (FLHS)	<i>SRCAP</i> (136140)
Gabriele-de Vries syndrome (GADEVS) ²	<i>YY1</i> (617557)
Genitopatellar syndrome (see also Ohdo syndrome) (GTPTS) ^{2,21}	<i>KAT6B</i> (606170)
Hao-Fountain syndrome (HAFOUS)	<i>USP7</i> (616863)
Helsmoortel-van der Aa syndrome (HVDAS) ²²	<i>ADNP</i> (615873)
Helsmoortel-van der Aa syndrome (HVDAS), Sifrim-Hitz-Weiss syndrome (SIHIWES) ^{54*}	<i>ADNP, CHD4</i> (615873, 617159)
Hunter-McAlpine craniosynostosis syndrome ²³	Chr5q35 duplication including <i>NSD1</i> (601379)
Hypercholesterolemia, familial, 1 (FHCL1) ^{24†}	<i>LDLR</i> (143890)
Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency*†	<i>AHCY</i> (613752)
Immunodeficiency-centromeric instability-facial anomalies syndromes 1-4 (ICF1, ICF2, ICF3, ICF4) ^{2,25}	<i>DNMT3B, CDCA7, ZBTB24, HELLS</i> (242860, 614069, 616910, 616911)
Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant (IMD31C)*	<i>STAT1</i> (614162)
Intellectual developmental disorder with autism and macrocephaly (IDDAM) ²	<i>CHD8</i> (615032)
Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities (IDDFBA)†	<i>FBXO11</i> (618089)
Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism (IDDMOH) ²	<i>SOX11</i> (615866)
Intellectual developmental disorder with seizures and language delay (IDDSELD)	<i>SETD1B</i> (619000)
Intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities (IDDSFTA) ²	<i>BCL11B</i> (618092)
Intellectual developmental disorder, autosomal dominant 7 (MRD7)*	<i>DYRK1A</i> (600855)
Intellectual developmental disorder, autosomal dominant 21 (MRD21)*	<i>CTCF</i> (615502)
Intellectual developmental disorder, autosomal dominant 23 (MRD23) ^{2,26}	<i>SETD5</i> (615761)
Intellectual developmental disorder, autosomal dominant 23 (MRD23); KBGS syndrome (KBGS) ^{2*}	<i>SETD5, ANKRD11</i> (615761, 148050)
Intellectual developmental disorder, autosomal dominant 29 (MRD29)*	<i>SETBP1</i> (616078)
Intellectual developmental disorder, autosomal dominant 51 (MRD51) ^{2,6}	<i>KMT5B</i> (617788)
Intellectual developmental disorder, autosomal dominant 57 (MRD57)†	<i>TLK2</i> (618050)



Intellectual developmental disorder, autosomal dominant 58 (MRD58)*	<i>SET</i> (618106)
Intellectual developmental disorder, autosomal recessive 65 (MRT65), KDM5B-related neurodevelopmental disorder*	<i>KDM5B</i> (618109)
Intellectual developmental disorder, X-linked 93 (XLID93) ^{2,6,44}	<i>BRWD3</i> (300659)
Intellectual developmental disorder, X-linked 97 (XLID97) ^{2,27}	<i>ZNF711</i> (300803)
Intellectual developmental disorder, X-linked 112 (XLID112) ^{2†}	<i>ZMYM3</i> (301111)
Intellectual developmental disorder, X-linked syndromic, Lubs type (MRXSL)*	<i>MECP2</i> (300260)
Intellectual developmental disorder, X-linked syndromic, Nascimento type (MRXSN) ^{1,2}	<i>UBE2A</i> (300860)
Intellectual developmental disorder, X-linked, syndromic, Armfield type (MRXSA) ^{1,2}	<i>FAM50A</i> (300261)
Intellectual developmental disorder, X-linked, syndromic, Claes-Jensen type (MRXSCJ) ^{6,28}	<i>KDM5C</i> (300534)
Intellectual developmental disorder, X-linked syndromic, Siderius type (MRXSSD) ^{1†}	<i>PHF8</i> (300263)
Intellectual developmental disorder, X-linked, syndromic, Snyder-Robinson type (MRXSSR) ^{1,2}	<i>SMS</i> (309583)
Jacobs syndrome (XYY)*	ChrY duplication
Kabuki syndrome 1 (KABUK1) ²⁹	<i>KMT2D</i> (147920)
Kabuki syndrome 1 and 2 (KABUK1, KABUK2)	<i>KMT2D</i> , <i>KDM6A</i> (147920, 300867)
Kabuki syndrome 2 (KABUK2) ²⁹	<i>KDM6A</i> (300867)
Karayol-Borroto-Haghshenas neurodevelopmental syndrome (KBHS) ^{2*}	<i>MSL2</i> (620985)
KAT6-related syndromes*	<i>KAT6A</i> , <i>KAT6B</i> (601408, 605880)
KBG syndrome (KBGS) ²⁶	<i>ANKRD11</i> (148050)
KDM2B-related syndrome	<i>KDM2B</i> (609078)
Kleefstra syndrome 1 (KLEFS1)	<i>EHMT1</i> (610253)
Klinefelter Syndrome ³⁰	ChrX duplication; 47,XXY
KMT2C-related syndrome†*	<i>KMT2C</i> (606833)
Koolen-De Vries syndrome (KDVS)	<i>KANSL1</i> (610443)
Luscan-Lumish syndrome (LLS)	<i>SETD2</i> (616831)
MACROH2A1-associated syndrome*	<i>MACROH2A1</i> (610054)
MAU2-associated syndrome*	<i>MAU2</i> (614560)
Menke-Hennekam syndrome 1 and 2 (MKHK1, MKHK2) ³¹	<i>CREBBP</i> , <i>EP300</i> (618332, 618333)
Mowat-Wilson Syndrome (MOWS)	<i>ZEB2</i> (235730)
MSL2 associated syndrome ²	<i>MSL2</i> (614802)
Myhre syndrome (MYHRS)*	<i>SMAD4</i> (139210)
Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities (NECRC)†	<i>ZMYM2</i> (619522)
Neurodevelopmental disorder with or without autism or seizures (NEDAUS) ^{2*}	<i>CUL3</i> (619239)
Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities (NEDFBA)	<i>SRSF1</i> (620489)

Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language (NEDHSIL)	<i>MEF2C</i> (613443)
Neurodevelopmental disorder with impaired speech and hyperkinetic movements (NEDISHM) ^{46*}	<i>ZNF142</i> (618425)
Neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment (NEDMVIC)*	<i>DOHH</i> (620066)
Neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties (NEDRIHF) ^{46*}	<i>PURA</i> (616158)
Neurofibromatosis, type 1 (NF1) ^{2†}	<i>NF1</i> (162200)
Neuroocular syndrome ^{2,32*}	<i>PRR12</i> (619539)
Nicolaides-Baraitser syndrome (NCBRS) ¹³	<i>SMARCA2</i> (601358)
NOTCH1-associated syndrome ^{2†*}	<i>NOTCH1</i> (190198)
NSD2 duplication-related syndrome ³³	<i>NSD2</i> (602952)
Ohdo syndrome, SBBYSS variant (see also Genitopatellar syndrome) (SBBYSS) ^{2,21}	<i>KAT6B</i> (603736)
Okur-Chung neurodevelopmental syndrome (OCNDS) & Poirier-Bienvenu neurodevelopmental syndrome (POBINDS) ^{48*}	<i>CSNK2A1, CSNK2B</i> (617062, 618732)
Phelan-McDermid syndrome (PHMDS) ³⁴	Chr22q13.3 deletion (606232)
PHF12-related syndrome†	<i>PHF12</i> (618645)
Pitt-Hopkins Syndrome (PTHS)	<i>TCF4</i> (610954)
Pitt-Hopkins syndrome (PTHS); Craniosynostosis 3 (CRS3)*	<i>TCF4, TCF12</i> (610954, 615314)
Potocki-Lupski syndrome (PTLS) ³⁵	Chr17p11.2 duplication (610883)
PTBP1-associated syndrome (PTBP1)*	<i>PTBP1</i> (600693)
Rahman syndrome (RMNS)	<i>HIST1H1E</i> (617537)
Rauch-Steindl syndrome (RAUST)*	<i>NSD2</i> (619695)
Recurrent constellations of embryonic malformations ^{36†}	Not applicable
Renpenning syndrome (RENS1) ^{1,2}	<i>PQBP1</i> (309500)
ReNU syndrome (RENU)*	<i>RNU4-2</i> (620851)
RNU2-2 associated syndrome (RNU2-2) ^{46*}	<i>RNU2-2</i> (621238)
Rubinstein-Taybi syndrome 1 (RSTS1) ³⁷	<i>CREBBP</i> (180849)
Rubinstein-Taybi syndrome 1 and 2 (RSTS1, RSTS2)	<i>CREBBP, EP300</i> (180849, 613684)
Rubinstein-Taybi syndrome 2 (RSTS2) ³⁷	<i>EP300</i> (613684)
Schizel-Giedion midface retraction syndrome (SGMRS)*	<i>SETBP1</i> (269150)
Schuurs-Hoeijmakers syndrome (SHMS)†	<i>PACS1</i> (615009)
SETD1A-related syndrome†*	<i>SETD1A</i> (611052)
Sex Chromosome Aneupoidy: Trisomy X, Klinefelter syndrome, XYY syndrome/Jacobs syndrome*	ChrX, ChrY
Sifrim-Hitz-Weiss syndrome (SIHIWES) ⁵²	<i>CHD4</i> (617159)
SMARCA5-associated syndrome (SMARCA5)*	<i>SMARCA5</i> (603375)
SMARCA5-related syndrome; Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (SMARCA5_NEDDFL)*	<i>SMARCA5, BPTF</i> (603375, 617755)
Smith-Kingsmore syndrome (SKS)*	<i>MTOR</i> (616638)
Smith-Magenis syndrome (SMS) ³⁸	Chr17p11.2 deletion (182290)

Sotos syndrome (SOTOS)	<i>NSD1</i> (117550)
Tatton-Brown-Rahman syndrome (TBRS) ²	<i>DNMT3A</i> (615879)
Tessadori-Bicknell-van Haaften neurodevelopmental syndrome 1, 3 and 4 (TEBIVANED1, TEBIVANED3, TEBIVANED4) [†]	<i>H4C3, H4C4, H4C5, H4C9</i> (619758, 602823, 619950, 619951)
Trisomy X (XXX)*	ChrX triplication
Turner Syndrome	ChrX deletion; 45,X; Monosomy X
Uniparental disomy of chromosome 16 (UPD16)*	Chr16
Velocardiofacial syndrome (VCFS) ³⁹	Chr22q11.2 deletion (192430)
WAPL-associated syndrome (WAPL)*	<i>WAPL</i> (610754)
WAPL-associated syndrome, PDS5A-associated syndrome, PDS5B-associated syndrome (WAPL-PDS5A-PDS5B) ^{52*}	<i>WAPL, PDS5A, PDS5B</i> (610754, 613200, 605333)
Weaver syndrome; Cohen-Gibson syndrome; Imagawa-Matsumoto syndrome (PRC2) ^{36*}	<i>EZH2, EED, SUZ12</i> (277590, 617561, 618786)
White-Kernohan syndrome ⁸	<i>DDB1</i> (619426)
White-Sutton syndrome (WHSUS)	<i>POGZ</i> (616364)
Wieacker-Wolff Syndrome (WRWF) ^{1,2}	<i>ZC4H2</i> (314580)
Wiedemann-Steiner syndrome (WDSTS)	<i>KMT2A</i> (605130)
Williams-Beuren region duplication syndrome ⁴⁰	Chr7q11.23 duplication (609757)
Williams-Beuren syndrome (WBS) ⁴¹	Chr7q11.23 deletion (194050)
Witteveen-Kolk syndrome (WITKOS) ²	<i>SIN3A</i> (613406)
Wolf-Hirschhorn syndrome (WHS) & Rauch-Steindl Syndrome (RAUST) ⁴²	Chr4p16.13 deletion, <i>NSD2</i> (194190, 602952)
Xia-Gibbs syndrome (XIGIS) ^{52*}	<i>AHDC1</i> (615829)

*These disorders are new for V6 of the EpiSign™ classifier.

†These episignatures are available for EpiSign™ Single requests only, not available through EpiSign™ METRIC.

¹ Defined with male cases only. Heterozygotes have been shown to not match the episignature.

² Reduced sensitivity may be observed.

³ The range of validated coordinates is 1p36.11(26,964,202-27,099,490). CNVs overlapping or expanding this region may also be detected.

⁴ Patients with other BAFopathy genes may be detected, but not confirmed in our experiments.

⁵ Only for variants near c.6200. No separate episignature due small cohort size, however these samples cluster separately from other BAFopathy/CSS1&2 samples.

⁶ Healthy carriers and those with incomplete penetrance are detectable.

⁷ Patients with biallelic variants are distinguishable from those with monoallelic variants.

⁸ This is a secondary episignature; sample must also be positive for CHU_BFL_WHI.

⁹ Only for variants within the amino acid range of 3400-3700.

¹⁰ The range of validated coordinates is 1p36.33p36.32(1,019,753-2,867,961). CNVs overlapping or expanding this region may also be detected.

¹¹ The range of validated coordinates is 19p13.13p13.2(13,201,983-13,213,144). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. NFIX sequence variants have been shown to not match the episignature.

¹² The range of validated coordinates is Xp11.22(53,559,057-53,654,518). CNVs overlapping or expanding this region may also be detected.

¹³ This is a secondary episignature; sample must also be positive for BAFopathy.

¹⁴ Only for variants near c.2656. No separate episignature due small cohort size however these samples cluster separately from other BAFopathy/CSS4 samples.

¹⁵ Male CdLS5 patients (HDAC8 mutations) may be detected, but not confirmed in our experiments.

-
- ¹⁶ Heterozygotes have been shown to not match the episignature.
- ¹⁷ Only for variants within the amino acid range of 960-1159.
- ¹⁸ Reduced sensitivity against other Diamond-Blackfan anemia disorders may be observed.
- ¹⁹ Patients with other FANC genes may be detected, but not confirmed in our experiments.
- ²⁰ Available as a targeted request only.
- ²¹ GTPS and SBBYSS are both caused by KAT6B mutations. We will report both regardless of which one is requested.
- ²² ADNP consists of two distinct episignatures dependent on variant location. HVDAS_T includes variants within the N- and C-terminus while HVDAS_C includes variants within the central region (approximately c.2054-2340).
- ²³ The range of validated coordinates is 5q35.2q35.3(175,839,681-176,904,798). CNVs overlapping or expanding this region may also be detected.
- ²⁴ Sensitivity against other hereditary hypercholesterolemia disorders has not been evaluated. Both monoallelic and biallelic cases are detected.
- ²⁵ ICF1 exhibits a unique episignature while ICF 2, 3 and 4 exhibit a distinct, shared episignature
- ²⁶ This is a secondary episignature; sample must also be positive for KBGS_MRD23.
- ²⁷ Heterozygotes have been shown to match the episignature.
- ²⁸ Heterozygotes have a distinct profile from hemizygotes.
- ²⁹ This is a secondary signature; sample must also be positive for combined Kabuki signature.
- ³⁰ XXX and YYY cases may also be detected.
- ³¹ Only for domain ID4. MKHK1/2 exhibit a shared ID4 domain episignature and therefore cannot distinguish between MKHK1 and MKHK2. Other domains of MKHK1/2 are not available for assessment.
- ³² Healthy carriers and those with incomplete penetrance are detectable. Reduced sensitivity may be observed.
- ³³ The range of validated coordinates is 4p16.3(1,832,733-1,975,031). CNVs overlapping or expanding this region may also be detected.
- ³⁴ The range of validated coordinates is 22q13.3(49,238,268-50,248,907). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. *SHANK3* sequence variants have been shown to not match the episignature.
- ³⁵ The range of validated coordinates is 17p11.2(16,779,412-20,231,379). CNVs overlapping or expanding this region may also be detected. Reduced sensitivity may be observed.
- ³⁶ Includes cases with phenotypic presentation of OAV, OAVV, VACTERL and VATER.
- ³⁷ This is a secondary signature; sample must also be positive for combined RSTS signature.
- ³⁸ The range of validated coordinates is 17p11.2(17,322,913-18,515,769). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. *RAI1* sequence variants have been shown to not match the episignature.
- ³⁹ The range of validated coordinates is 22q11.21(19,510,547-20,285,090). CNVs overlapping or expanding these regions may be detected.
- ⁴⁰ The range of validated coordinates is 7q11.23(73,953,518-74,138,459). CNVs overlapping or expanding this region may also be detected.
- ⁴¹ CNVs overlapping or expanding 7q11.23 may also be detected.
- ⁴² The range of validated coordinates is 4p16.3(679,715-2,169,001). CNVs overlapping or expanding this region may also be detected. *NSD2* sequence variants have been shown to match the episignature.
- ⁴⁴ Defined with female cases only.
- ⁴⁵ There is a robust missense episignature for the condition. This is a new truncating episignature that is not as robust.
- ⁴⁶ Episignature developed using synthetic data.
- ⁴⁷ Episignature defined with 12 samples, 11 invdupdel and one del only. The del only does not match the identified pattern. Deletion only cases do not match the episignature.
- ⁴⁸ Signature detects variants in casein kinase II (CSNK2) subunits (CSNK2A1 and CSNK2B).
- ⁴⁹ Episignature may detect other Diamond-Blackfan anemia types.
- ⁵⁰ Truncating mutations outside of the FLHS region.
- ⁵¹ This episignature detects loss of function variants.
- ⁵² This episignature detects truncating variants.
- ⁵³ This is a secondary episignature; sample must also be positive for CdLS. Reduced sensitivity may be observed.
- ⁵⁴ Signature can detect HVDAS variants outside of the coding nucleotide range of c.2054-2340 and SIHIWES variants.
- ⁵⁵ Signature defined with missense variants at p.986 and p.987